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The apolipoprotein(a) size polymorphism is associated with
nephrotic syndrome.
Background. The atherogenic serum lipoprotein(a) [Lp(a)] is
significantly elevated in patients with nephrotic syndrome. The
underlying mechanism for this elevation is poorly understood.
Methods. We investigated in 207 patients with nondiabetic
nephrotic syndrome and 274 controls whether the apolipopro-
tein(a) [apo(a)] kringle-IV repeat polymorphism explains the
elevated Lp(a) levels in these patients.
Results. Patients showed a tremendous elevation of Lp(a)
concentrations when compared to controls (mean 60.4 vs.
20.0 mg/dL and median 29.8 vs. 6.4 mg/dL, P < 0.0001). Pri-
mary and secondary causes contributed to this elevation. The
primary causes became apparent by a markedly elevated num-
ber of low-molecular-weight apo(a) phenotypes which are usu-
ally associated with high Lp(a) levels. This frequency was 35.7%
in patients compared to only 24.8% in controls (P = 0.009). In
addition, secondary causes by the pathogenetic mechanisms of
the nephrotic syndrome itself resulted in a different increase
of Lp(a) in the various apo(a) isoform groups. Based on the
measured Lp(a) concentrations in each subject, we calculated
separately the Lp(a) concentrations arising from the two ex-
pressed isoforms by estimating the relative proportion of the
two serum isoforms in the sodium dodecyl sulfate (SDS) agarose
gel electrophoresis. Low-molecular-weight isoforms were asso-
ciated with 40% to 75% elevated Lp(a) concentrations when
compared to matched isoforms from controls. High-molecular-
weight apo(a) isoforms showed 100% to 500% elevated Lp(a)
levels compared to matched isoforms from controls. The sever-
ity of the nephrotic syndrome as well as the degree of renal
impairment did not influence the Lp(a) concentrations.
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Conclusion. The tremendously increased Lp(a) levels in
nephrotic syndrome ar caused by primary genetic as well as
disease-related mechanisms.
There is a large body of evidence that high lipopro-
tein(a) [Lp(a)] levels are a risk factor for cardiovascular
disease in the general population [1, 2]. This lipoprotein
shows a high degree of genetic determination. Briefly, a
size polymorphism at the apolipoprotein(a) [apo(a)] gene
locus [3] originating from a varying number of kringle-IV
(K-IV) repeats [4, 5] is the most important determinant
of Lp(a) levels that exhibit marked interindividual varia-
tion by more than 1000-fold. Subjects who express a low
number of K-IV repeats [low-molecular-weight (LMW)
apo(a) phenotypes] show on average markedly higher
Lp(a) concentrations than those with a high number of
K-IV repeats [high molecular weight (HMW) apo(a) phe-
notypes] who usually have low Lp(a) concentrations. Re-
cent studies that considered Lp(a) concentrations as well
as the apo(a) size polymorphism found that the apo(a)
size polymorphism determines the atherothrombotic risk
not only by its allelic control of Lp(a) concentrations but
also per se. Identical Lp(a) levels going in hand with ei-
ther small or large apo(a) isoforms are associated with
different risk. Elevated Lp(a) levels showed a higher risk
for carotid stenosis [6] or coronary artery disease [7] if
coinciding with small isoforms than those coinciding with
large isoforms.
Numerous studies have reported that Lp(a) levels are
significantly elevated in patients with nephrotic syndrome
[8–18]. However, it was never systematically investigated
whether and how the apo(a) kringle-IV repeat polymor-
phism contributes to this increase. We therefore com-
pared the apo(a) phenotype distribution in patients and
controls and considered the relative expression of the two
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Table 1. Characteristics of patients with nephrotic syndrome and
age- and gender-matched controlsa
Controls Nephrotic syndrome
(N = 274) (N = 207)
Age years 44.6 ± 12.4 43.5 ± 16.0
Gender, females/males 97/177 76/131
Body mass index 26.1 ± 3.7 25.1 ± 3.9c
Creatinine clearance 101 ± 27 73 ± 40
mL/min [84, 97, 113] [40, 68, 98]b
Creatinine mg/dL 0.99 ± 0.17 1.83 ± 1.38b
Urea mg/dL 31 ± 8 55 ± 35b
Proteinuria — 7.1 ± 3.6
g/24 hours/1.73 m2 [4.4, 6.0, 8.6]
Serum albumin g/dL 4.88 ± 0.47 3.01 ± 0.96b
Total protein g/dL 7.0 ± 0.4 5.9 ± 1.1b
Primary cause of renal
disease
Membranous 51 (24.6%)
nephropathy
Minimal change 34 (16.4%)
nephropathy
Focal segmental 30 (14.5%)
glomerulosclerosis
IgA nephropathy 30 (14.5%)
Membranoproliferative 18 (8.7%)
glomerulonephritis
Crescentic 5 (2.4%)
glomerulonephritis
Nephrosclerosis 5 (2.4%)
Amyloidosis 9 (4.3%)
Lupus nephritis 10 (4.8%)
Others 15 (7.4%)
aData are mean ± SD and [25th percentile, median, 75th percentile] where
appropriate; bP < 0.001; and cP < 0.01 for comparison with controls.
isoforms to calculate the apo(a) isoform-specific effects
on Lp(a) levels.
METHODS
Patients
The 207 patients with nephrotic syndrome included in
this study came from three centers: (1) 155 (75%) were
recruited at the Department of Nephrology at the Uni-
versity of Innsbruck during a period of 11 years (1992
to 2002); (2) 37 patients were recruited in the Munich
University Hospital and in outpatient clinics in Bavaria;
and (3) 15 patients were recruited at the Department
of Nephrology and Rheumatology at the University of
Du¨sseldorf. The primary cause of renal disease was di-
agnosed by kidney biopsy and nephrotic syndrome was
defined by a 24-hours proteinuria with more than 3.5 g/
24 hours. Patients with diabetic nephropathy were ex-
cluded from the study since they usually do not un-
dergo a kidney biopsy in our centers. All patients were
Caucasians and were not in need of renal replacement
therapy.
Table 1 shows the clinical characteristics of patients,
including the histologic diagnosis of the primary cause of
renal disease.
Patients were compared to 274 age- and gender-
matched controls of the same ethnic origin without renal
impairment or liver disease who were recruited in 1997
from one of the PROCAM study centers [19].
Laboratory procedures
Serum and ethylenediaminetetraacetic acid (EDTA)
plasma were taken after a 12-hour overnight fast. After
low-speed centrifugation, samples were frozen and kept
at −80◦C prior to analysis [20]. Samples were measured
in batches to avoid major effects of long-term storage on
the measured Lp(a) levels. We calculated the creatinine
clearance using the formula of Cockcroft and Gault [21].
Measurement of serum albumin, Lp(a), and apo(a)
phenotyping were performed in batches centrally in a
single laboratory to avoid interlaboratory differences in
measurements. Serum albumin concentrations were mea-
sured by the brom-cresol green method kit from Roche
(Mannheim, Germany). Lp(a) quantification was per-
formed as described in detail [20] with a double-antibody
enzyme-linked immunosorbent assay (ELISA) using an
affinity-purified polyclonal apo(a) antibody for coating
and the horseradish peroxidase-conjugated monoclonal
1A2 for detection. An Lp(a) positive serum from Techn-
oclone (Vienna, Austria) with the same apo(a) isoforms
served as standard throughout the study. Each sample
was analyzed in duplicate, and intra- and interassay co-
efficients of variation were 2.7% and 6%, respectively.
Apo(a) phenotyping was performed by sodium dodecyl
sulfate (SDS)-agarose gel electrophoresis under reduc-
ing conditions as outlined with slight modifications [22].
Fifty nanograms of Lp(a) were applied to the gel in case
of serum Lp(a) concentrations above 4 mg/dL. In case
of lower concentrations, a fixed volume of 1.5 lL serum
was applied to the gel. Electrophoresis was followed by
immunoblotting [3] using the monoclonal antibody 1A2
for detection of apo(a) isoforms.
Calculation of the Lp(a) concentration derived
from each apo(a) isoforms
In subjects expressing two apo(a) isoforms, we esti-
mated the percentage of the two isoforms by densitomet-
ric scanning of the apo(a) bands of the immunoblots from
SDS agarose gel electrophoresis. We used the Lp(a) con-
centrations measured by ELISA to calculate the isoform-
specific amount of Lp(a) derived from each isoform by
using these relative estimates [23]. For example, when
an individual with 21 and 33 K-IV repeats had an Lp(a)
serum concentration of 40 mg/dL measured by ELISA,
and the 21 K-IV isoform accounted for 85% of the stain-
ing in the SDS agarose gel electrophoresis, we calculated
the Lp(a) concentration originating from this isoform to
be 34 mg/dL (40 · 0.85). The isoform with 33 K-IV repeats
accounted for the remaining 6 mg/dL. The whole Lp(a)
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concentration counted for the expressed isoform in case
a subject showed only one apo(a) band.
Statistical procedures
Statistical analyses were performed with Statistical
Package for the Social Sciences (SPSS) for Windows 11.0.
Univariate comparisons of continuous variables between
controls and nephrotic patients were done by unpaired
t test or the nonparametric Wilcoxon rank sum test in
case of nonnormally distributed variables. Lp(a) levels
between more than two groups were compared by the
Kruskal-Wallis test. Dichotomized variables were com-
pared using Pearson’s v 2 test or the Likelihood ratio v 2
test. The Spearman correlation test was used to correlate
Lp(a) with proteinuria, creatinine clearance, and serum
concentrations of albumin and total protein.
Because of the high number of detectable apo(a) iso-
forms (>30), many phenotypes were represented only in
low numbers. To account for this problem, we decided
a priori to combine apo(a) isoforms in six groups ac-
cording to the molecular weight of the smaller apo(a)
isoforms in order to have sufficient sample sizes in each
category. Furthermore, we divided apo(a) phenotypes
into two subgroups according to the molecular weight
of the smaller apo(a) isoforms, as done in previous works
by our and other groups [6, 24–31]. The LMW group in-
cluded all subjects with at least one apo(a) isoform with
11 to 22 K-IV repeats; the HMW group comprised all
subjects having only isoforms with more than 22 K-IV re-
peats. In a subanalysis, however, we considered the effect
of the second apo(a) isoform, if expressed, as described
above.
RESULTS
Comparison of nephrotic patients and controls
Table 1 shows the demographic and laboratory char-
acteristics of the investigated nephrotic patients and the
age- and gender-matched healthy controls. Patients lost
on average 7.1 g proteins per day in urine and showed an
impaired creatinine clearance of 66 mL/min/1.73 m2. As a
consequence of the nephrotic syndrome, patients showed
markedly decreased serum albumin concentrations when
compared to controls (3.10 vs. 4.88 g/dL, P < 0.001). Most
patients underwent biopsy when kidney function was
still relatively well preserved (creatinine clearance 73 ±
40 mL/min).
Patients with nephrotic syndrome showed a tremen-
dous elevation of Lp(a) serum concentrations. The mean
and median concentrations were three and five times
higher, respectively, when compared to controls (mean
60.4 vs. 20.0 mg/dL and median 29.8 vs. 6.4 mg/dL,
respectively) (Table 2). Figure 1 shows the frequency
distribution of Lp(a) levels in the investigated groups.
Table 2. Lipoprotein(a) [Lp(a)] serum concentrations and
apolipoprotein(a) [apo(a)] size polymorphism in controls and patients
with nephrotic syndrome
Nephrotic
Controls syndrome
(N = 274) (N = 207)
Lp(a) mg/dL; mean ± SD 20.0 ± 32.8 60.4 ± 85.4a
[25th percentile, median, [2.0, 6.4, 18.5] [9.6, 29.8, 81.1]
75th percentile]
Apo(a) alleles number; (%)b
11–19 K-IV repeats 21 (7.7) 23 (11.1)
20–22 K-IV repeats 47 (17.2) 51 (24.6)
23–25 K-IV repeats 38 (13.9) 30 (14.5)
26–28 K-IV repeats 59 (21.5) 35 (16.9)
29–31 K-IV repeats 55 (20.1) 40 (19.3)
>31 K-IV repeats 54 (19.7) 28 (13.5)
Apo(a) phenotypesc
Low-molecular-weight apo(a) 68 (24.8) 74 (35.7)
phenotypes number; (%)
High-molecular-weight apo(a) 206 (75.2) 133 (64.3)
phenotypes number; (%)
aP < 0.0001 by Wilcoxon rank sum test for comparison of Lp(a) serum
concentrations between patients and controls.
bMantel-Haenszel test for linear association comparing the frequencies of
apo(a) phenotypes between patients and controls: v 2 = 6.96, df = 1, P = 0.008.
cPearson’s v 2-test comparing the frequencies of LMW apo(a) phenotypes
between patients and controls: v 2 = 6.77, df = 1, P = 0.009.
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Fig. 1. Frequency distribution of lipoprotein(a) [Lp(a)] serum concen-
trations in 207 patients with nephrotic syndrome and 274 healthy con-
trols. Pearson’s v 2 test P < 0.0001.
Similar to earlier control groups we observed about 60%
of healthy subjects having Lp(a) levels below 10 mg/dL. In
nephrotic patients only 25% of the patients showed such
low levels. Instead, about 50% and 30% had Lp(a) levels
above 30 and 70 mg/dL, respectively. This could only be
observed in 18% and 8.4% of the controls, respectively.
In controls we observed the usual frequency of LMW
apo(a) phenotypes as in earlier studies. Patients with
nephrotic syndrome showed a markedly elevated num-
ber of LMW apo(a) phenotypes when compared to con-
trols (35.7% vs. 24.8%, P = 0.009) (Table 2). This higher
number of LMW apo(a) phenotypes was not caused by
the preponderance of a single isoform but by an eleva-
tion in the frequency of all LMW apo(a) isoforms. Next,
we investigated whether an association exists between
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Fig. 2. Influence of proteinuria and renal function on lipoprotein(a)
[Lp(a)] serum concentrations in patients with nephrotic syndrome. The
10th, 25th, 50th, 75th, and 90th percentile of Lp(a) serum concentra-
tions in groups of patients stratified by the medians of proteinuria and
creatinine clearance. No significant differences between the four groups
were observed (Kruskal-Wallis test, P = 0.59).
Lp(a) concentrations and/or apo(a) phenotypes on the
one hand and the five most frequent causes of renal dis-
ease. We observed no differences in the Lp(a) levels or
the frequency of LMW apo(a) phenotypes between these
five groups (data not shown).
The severity of the nephrotic syndrome as well as the
amount of renal impairment did not influence the Lp(a)
concentrations. There were no significant differences in
Lp(a) levels when patients were stratified by the medi-
ans of proteinuria and creatinine clearance (P = 0.59 by
Kruskal-Wallis test) (Fig. 2). A negative correlation was
observed between Lp(a) levels and serum total protein
(r = −0.20, P = 0.005) and serum albumin (r = −0.17,
P = 0.023).
We then analyzed whether the elevation of Lp(a) in
nephrotic syndrome can be observed in all apo(a) isoform
groups. Patients with LMW apo(a) phenotypes showed
Lp(a) levels almost twice as high as controls with the
same apo(a) phenotypes (mean ± SD; median 106.2 ±
115.2 mg/dL; 79.3 vs. 56.0 ± 47.4 mg/dL; 51.1 mg/dL,
P = 0.002). The relative elevation of Lp(a) was much
more pronounced in patients with HMW apo(a) pheno-
types who showed on average fourfold higher Lp(a) levels
(mean ± SD; median 34.9 ± 46.9 mg/dL; 17.7 vs. 8.2 ±
11.2 mg/dL; 4.2 mg/dL, P < 0.0001). The subgrouping
into LMW and HMW apo(a) phenotypes in a given in-
dividual, however, is based on the apo(a) isoform with
the lowest molecular weight. It ignores that many sub-
jects with an LMW apo(a) phenotype have not only one
LMW, but also one HMW apo(a) isoform. Therefore, we
calculated based on the measured Lp(a) concentrations
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Fig. 3. Median lipoprotein(a) [Lp(a)] serum concentrations in patients
with nephrotic syndrome and controls stratified by six apo(a) isoform
groups. Lp(a) concentrations were calculated for each expressed apo(a)
isoform separately from the measured Lp(a) concentration by estimat-
ing the relative proportion of the two isoforms in the sodium dodecyl
sulfate (SDS) agarose gel electrophoresis (see Methods section).
in each subject separately the Lp(a) concentrations aris-
ing from the two expressed isoforms by estimating the rel-
ative proportion of the two isoforms in the SDS agarose
gel electrophoresis (see Methods section for details about
the calculation). Figure 3 shows that isoforms with 11 to
19 and 20 to 22 K-IV repeats from nephrotic patients
were associated with 1.75- and 1.4-fold elevated Lp(a)
concentrations, respectively, when compared to matched
isoforms from controls. Those from patients with HMW
apo(a) isoforms were associated with two- to more than
sixfold elevated Lp(a) levels.
DISCUSSION
Patients with nephrotic syndrome have a significantly
increased burden of corornary heart disease [32, 33].
The hyperlipidemic changes in these patients might
contribute to this increased risk [34]. One of the most
prominent changes of the lipoprotein metabolism is ex-
perienced by Lp(a): there is no other disease condition
known which produces such an extensive increase in
Lp(a) levels as the nephrotic syndrome [8–18]. We there-
fore investigated the changes of Lp(a) in these patients
in more detail by apo(a) phenotyping and estimation of
apo(a) isoform-derived Lp(a) concentrations.
Primary causes for increased Lp(a) concentrations
Surprisingly, we observed primary as well as secondary
reasons to contribute to the three and five times higher
mean and median Lp(a) levels, respectively. The primary
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or genetic reasons became obvious when we looked at
the apo(a) phenotype distribution between patients and
controls. Patients showed a 1.5 times higher frequency of
LMW apo(a) phenotypes than controls (35.7% vs. 24.8%,
P = 0.009). The obtained results in nephrotic patients are
in contrast to those in nonnephrotic renal disease patients
as well as dialysis patients where increased Lp(a) levels
were found to be caused solely by nongenetic disease-
related mechanisms [23, 26, 29, 31, 35, 36]. We are aware
that case control studies include the possibility of false
positive results. However, a finding by chance is not very
likely due to the large number of patients and controls
we investigated. Furthermore, a spurious association is
improbable, since we observed in the controls of the
study at hand a very similar apo(a) phenotype distribu-
tion as in our earlier studies which used controls from the
same geographic regions as our nephrotic patients [31,
35, 37].
Interestingly, our finding of differences in the fre-
quency of LMW apo(a) phenotypes between patients and
controls is supported by another data set. Paying closer
attention to Table 4 of the study by Wanner et al [10],
one can calculate a 1.6 times higher frequency of LMW
apo(a) phenotypes in 60 nephrotic patients compared to
91 controls of that study.
If this higher frequency of LMW apo(a) phenotypes in
nephrotic patients indeed holds true, we might speculate
that high Lp(a) levels [besides high low-density lipopro-
tein (LDL) cholesterol levels] caused partially by a
preponderance of LMW apo(a) phenotypes have an
modulating effect on proteinuria by influencing the en-
dothelial and glomerular function. Atherogenic lipopro-
teins such as LDL cholesterol or Lp(a), especially when
oxidized, have pronounced effects on this system. They
induce the formation of oxygen radicals in arteries, in
glomeruli, and in juxtaglomerular cells, which results in
an inhibition of nitric oxide-mediated vasodilatation [38],
stimulation of renin release, and modulation of mesan-
gial cell growth and apoptosis [39–42]. Amelioration of
oxidative stress by the use of antioxidants prevents the
induction of apoptosis [42, 43]. The Heymann nephritis
as rat model of human membranous glomerulopathy, a
frequent cause of nephrotic syndrome in humans, clearly
shows that proteinuria in this model depends on the
formation of radical oxygen species. Therapeutic appli-
cation of oxygen radical scavengers drastically reduces
proteinuria [44, 45]. In accordance, treatment of rats with
Heymann nephritis as well as of humans suffering from
membranous nephropathy with probucol, a potent in-
hibitor of lipid peroxidations, resulted in a reduction of
proteinuria [46, 47]. The treatment with lovastatin had no
effect on proteinuria although it showed a similar LDL
cholesterol-lowering effect [47]. Therefore, the specific
antiproteinuric effect of probucol seems to be indepen-
dent of the lipid-lowering effect.
An influence of high Lp(a) levels on the progression
of a glomerular disease in terms of nephrotic or non-
nephrotic course is in line with two observations. First,
in a recent study, high Lp(a) levels predicted the fu-
ture relapse in children with steroid-sensitive nephrotic
syndrome [18]. Second, in patients with nonnephrotic
glomerulonephritis who do not show these tremendous
elevations of Lp(a), we observed an apo(a) phenotype
frequency distribution that is not different from controls
[23]. Until now, only one prospective study investigated
the influence of Lp(a) on the progression of renal disease
which was negative [48]. This study, however, was small
and only 17 of the 73 patients showed a proteinuria above
3 g/24 hours.
Secondary causes for increased Lp(a) concentrations
The secondary causes for an Lp(a) elevation in
nephrotic syndrome became apparent when we found
that Lp(a) was elevated in all apo(a) isoform classes when
compared to the isoform-matched controls. In principle,
this was already observed in a smaller study by Wanner
et al [10]. The stratification of apo(a) phenotypes in that
study, however, was based on the apo(a) isoform with the
most intensive immunostaining. Since the sensitivity of
the apo(a) phenotyping methods significantly improved
during the last 10 years, we used in the present study
the immunostaining of the apo(a) bands to calculate the
proportion of Lp(a) deriving from each apo(a) isoform.
This analytic method diminishes the problem of catego-
rizing patients into groups of apo(a) phenotypes depend-
ing on the smaller apo(a) isoform or on the isoform which
was expressed more dominantly. Using this method, we
herein clearly demonstrate that Lp(a) is elevated in all
apo(a) isoform groups but show that HMW apo(a) iso-
forms are associated with a more pronounced relative
elevation of Lp(a) than LMW apo(a) isoforms when com-
pared to isoform-matched controls. This is in contrast to
nonnephrotic patients with mild and moderate renal in-
sufficiency who show an apo(a) isoform-specific elevation
of Lp(a) meaning that Lp(a) raises only in HMW apo(a)
isoforms but not in LMW isoforms [23]. This interesting
but until now unexplained phenomenon was already de-
scribed earlier for hemodialysis patients by our and other
groups [26, 29, 31, 35, 36]. Continuous ambulatory peri-
toneal dialysis (CAPD) patients show an extent of Lp(a)
elevation in between of hemodialysis and nephrotic pa-
tients. Besides an elevation of Lp(a) in HMW apo(a) phe-
notypes CAPD patients with LMW apo(a) types show a
tendency to elevated Lp(a) levels [31]. Taken together,
it seems that the large amount of protein loss either by
dialysate in CAPD patients or in urine in nephrotic pa-
tients results in an increased production of Lp(a) by the
liver. This was indeed observed in recent turnover stud-
ies in patients with nephrotic syndrome which revealed
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a similar fractional catabolic rate of Lp(a) in five pa-
tients and five controls which suggested that differences
in Lp(a) levels are caused by differences in synthesis rate
[49]. The number of studied patients did not allow to in-
vestigate the turnover stratified for apo(a) phenotypes.
The data from the present study, however, suggest that
even when Lp(a) is elevated in all apo(a) isoform groups,
we can observe again that HMW apo(a) isoforms show a
higher relative (but not absolute) increase in Lp(a) levels
than LWM apo(a) isoforms.
Similar to other studies [8, 10, 13] we did not find any
correlation between Lp(a) and the amount of protein loss
or kidney function. The urinary protein loss in nephrotic
syndrome seems to be already above a certain threshold
where it has a linear influence on Lp(a) levels. Above this
threshold neither the amount of proteinuria nor of renal
function was associated with a further increase in Lp(a)
concentrations. Obviously, the increased hepatic synthe-
sis of lipoproteins, including Lp(a), dominates the serum
levels independently of these two parameters. Lp(a) was
only correlated with total serum protein and serum albu-
min. Hypoalbuminemia might result in a reduced oncotic
pressure, which, in turn, stimulates the hepatic synthesis
of albumin and other proteins including lipoproteins and
Lp(a) [50, 51].
CONCLUSION
We show in this investigation that primary (genetic)
and secondary causes are responsible for the extremely
elevated Lp(a) levels in nephrotic syndrome. The pre-
ponderance of LMW apo(a) phenotypes let us speculate
that Lp(a) has an influence on nephrotic proteinuria.
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